Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 23.7% in February

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the target of a significant increase in short interest in February. As of February 15th, there was short interest totalling 713,000 shares, an increase of 23.7% from the January 31st total of 576,400 shares. Based on an average daily volume of 363,700 shares, the days-to-cover ratio is currently 2.0 days. Approximately 27.0% of the shares of the company are short sold.

Hedge Funds Weigh In On Aligos Therapeutics

Several hedge funds have recently modified their holdings of ALGS. AlphaMark Advisors LLC lifted its holdings in shares of Aligos Therapeutics by 1,000.0% in the fourth quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company’s stock valued at $44,000 after buying an additional 1,000 shares during the period. Drive Wealth Management LLC acquired a new position in Aligos Therapeutics during the fourth quarter worth about $916,000. Golden State Wealth Management LLC bought a new stake in Aligos Therapeutics in the fourth quarter worth about $107,000. Charles Schwab Investment Management Inc. lifted its holdings in Aligos Therapeutics by 19.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 14,286 shares of the company’s stock valued at $569,000 after acquiring an additional 2,306 shares during the last quarter. Finally, Avantax Advisory Services Inc. bought a new position in shares of Aligos Therapeutics during the 4th quarter valued at about $1,218,000. 60.43% of the stock is currently owned by institutional investors and hedge funds.

Aligos Therapeutics Price Performance

NASDAQ ALGS opened at $14.34 on Wednesday. Aligos Therapeutics has a 12 month low of $6.76 and a 12 month high of $46.80. The firm has a market capitalization of $51.45 million, a PE ratio of -1.08 and a beta of 2.45. The company’s 50 day simple moving average is $28.91 and its 200 day simple moving average is $20.59.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $75.00 target price on shares of Aligos Therapeutics in a research report on Thursday, November 7th.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).